Neurodegenerative Disease Market By Drug Class 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Neurodegenerative Disease Market
Neurodegenerative Disease Market: By Drug Class (NMDA, SSRIs, Dopamine Inhibitors) & by Indications (Parkinson’s & Huntington disease, Amyotrophic Lateral Sclerosis, Alzheimer’s disease) & Geography-Forecast (2016-2021)
Report Code : HCR 0303
Published On: 15 January, 2016   Updated On: 15 January, 2016

  • Report Description
  • Table of Contents
  • Customization Options
Neurodegenerative disease or neurodegeneration is disease which is causes the progressive damage or wear and tear of the nerve cells. This disease causes loss of abilities like decision making and eventually memory loss. This diseases are debilitating and incurable conditions which results in progressive degeneration of neurons and lead to problems with mental functioning and movement. Major cause of neurodegeneration could be deposition of toxic protein substance in the brain or loss of functionality/improper functioning of mitochondria present in brain. Patients generally show mixture of symptoms for one or more neurodegenerative disease. The prevalence of these conditions is on a constant rise across the globe, yet there is a general lack of effective therapies to treat the same.

 Neurodegenerative Disease Market

Geographically North America dominated global neurodegenerative disease market, due to advanced medical infrastructure and approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region.

This report identifies the peripheral intervention market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Neurodegenerative Disease market.
  • This report is segmented into three major drug type. Some of the major drug type covered  in this report are as follows: NMDA, SSRIs, Dopamine Inhibitors
  • This report is segmented into three major indicators. Some of the major indicators covered  in this report are as follows: Parkinson’s & Huntington disease, Amyotrophic Lateral Sclerosis, Alzheimer’s disease and Others
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Neurodegenerative Disease in each of the region.

This report identifies all the major companies operating in the global Neurodegenerative Disease market. Some of the major companies’ profiles in detail are as follows:
  • Novartis
  • Pfizer
  • Merck Serono
  • Biogen Idec
  • TEVA Pharmaceuticals Industries
1. Neurodegenerative Disease– Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Neurodegenerative Disease– Market Forces
   4.1. Drivers
      4.1.1. Rapidly ageing population with increasing risk of developing neurological disorders
   4.2. Opportunities
      4.2.1. Increasing awareness in the developing nations
   4.3. Challenges
   4.4. Porter’s Five Forces Analysis
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bargaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Neurodegenerative Disease– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Neurodegenerative Disease Market, By Drug class
   6.1. NMDA
   6.2. SSRIs
   6.3. Dopamine Inhibitors
   6.4. Others
7. Neurodegenerative Disease Market, By Indications
   7.1. Parkinson’s & Huntington disease
   7.2. Amyotrophic Lateral Sclerosis
   7.3. Alzheimer’s disease]Chemotherapy
   7.4. Others
8. Neurodegenerative Disease Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Neurodegenerative Disease– Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Top 10 Companies)
   10.1. Novartis
   10.2.  Pfizer
   10.3. Merck Serono
   10.4. Biogen Idec
   10.5. TEVA Pharmaceuticals Industries
   10.6. UCB
   10.7. Boehringer Ingelheim
   10.8. Sanofi S.A
   10.9. GlaxoSmithKline
   10.10. Neuro-Hitech, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll